Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,056.80
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.23
(
0.02%
)
Bitcoin
77,761.22
(
-0.66%
)
News Focus
News Focus
Post# of 957
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jondoeuk

Send PM Follow Ignore
Followers 37
Posts 3475
Boards Moderated 1
Alias Born 10/24/2015

jondoeuk

Re: NY1972 post# 845

Saturday, 12/13/2025 7:03:51 PM

Saturday, December 13, 2025 7:03:51 PM

Post# of 957
New deck https://ir.fatetherapeutics.com/static-files/4f345e9c-b921-4a4d-a363-d22c87362052

The want to complete dose escalation cohorts of FT836 in solid tumours by mid 2026 (I put that up to Q3 2026).

They also want to complete phase one SLE cohort enrollment by mid-2026 and activate up to forty sites for pivotal trial readiness. Also gain FDA alignment on registrational protocol and initiate a pivotal trial in 2026 as well.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent FATE News
More FATE News